Cuervo G, Camoez M, Shaw E, Dominguez MÁ, Gasch O, Padilla B, Pintado V, Almirante B, Molina J, López-Medrano F, Ruiz de Gopegui E, Martinez JA, Bereciartua E, Rodriguez-Lopez F, Fernandez-Mazarrasa C, Goenaga MÁ, Benito N, Rodriguez-Baño J, Espejo E, Pujol M.

Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients

BMC INFECTIOUS DISEASES 2015. 15(1): 484-484. Nº de citas: 3

[doi:10.1186/s12879-015-1227-y]

Palladino C, Gómez ML, Soler-Palacín P, González-Tomé MI, De Ory SJ, Espiau M, Hoyos SP, León-Leal JA, Méndez M, Moreno-Pérez D, Guasch CF, Sierra AM, Guruceta IP, Guillén SM, Briz V.

Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

AIDS 2015. 29(16): 2155-2159. Nº de citas: 3

[doi:10.1097/QAD.0000000000000819]

Treviño A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V.

The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain

AIDS REVIEWS 2015. 17(4): 212-219. Nº de citas: 10

Muñoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodríguez-Abella H, Fariñas MC, Cobo Belaustegui M, Mestres C, Llinares P, Goenaga M, Navas E, Oteo JA, Tarabini P, Bouza E.

Current Epidemiology and Outcome of Infective Endocarditis A Multicenter, Prospective, Cohort Study

Medicine 2015. 94(43): . Nº de citas: 76

[doi:10.1097/MD.0000000000001816]

Navas E, Torner N, Broner S, Godoy P, Martínez A, Bartolomé R, Domínguez A.

Economic costs of outbreaks of acute viral gastroenteritis due to norovirus in Catalonia (Spain), 2010-2011

Bmc Public Health 2015. 15(1): 999-999. Nº de citas: 13

[doi:10.1186/s12889-015-2289-x]

García Comas L, Ordobás Gavín M, Sanz Moreno JC, Ramos Blázquez B, Gutiérrez Rodríguez A, Astray Mochales J, Moreno Guillén S.

Prevalence of hepatitis C antibodies in the population aged 16-80 years in the Community of Madrid 2008-2009.

JOURNAL OF MEDICAL VIROLOGY 2015. 87(10): 1697-1701. Nº de citas: 22

[doi:10.1002/jmv.24219]

San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network.

Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D plus /R- solid organ transplant recipients

TRANSPLANT INFECTIOUS DISEASE 2015. 17(5): 637-646. Nº de citas: 15

[doi:10.1111/tid.12417]

de Egea V, Muñoz P, Valerio M, de Alarcón A, Lepe JA, Miró JM, Gálvez-Acebal J, García-Pavía P, Navas E, Goenaga MA, Fariñas MC, Vázquez EG, Marín M, Bouza E.

Characteristics and Outcome of Streptococcus pneumoniae Endocarditis in the XXI Century A Systematic Review of 111 Cases (2000-2013)

Medicine 2015. 94(39): . Nº de citas: 33

[doi:10.1097/MD.0000000000001562]

Blanco JR, Arroyo-Manzano D, Rojas-Liévano JF, Crespo M, Bravo I, Pasquau J, Garcia Del Toro M, Herrero C, Rivero A, Moreno S, Llibre JM.

The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age

AIDS RESEARCH AND HUMAN RETROVIRUSES 2015. 31(9): 893-897. Nº de citas: 4

[doi:10.1089/aid.2015.0016]

Falcon A, Cuevas MT, Rodriguez-Frandsen A, Reyes N, Pozo F, Moreno S, Ledesma J, Martínez-Alarcón J, Nieto A, Casas I.

CCR5 deficiency predisposes to fatal outcome in influenza virus infection

JOURNAL OF GENERAL VIROLOGY 2015. 96(8): 2074-2078. Nº de citas: 42

[doi:10.1099/vir.0.000165]

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, HIV-CAUSAL Collaboration.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study

LANCET HIV 2015. 2(8): 335-343. Nº de citas: 37

[doi:10.1016/S2352-3018(15)00108-3]

Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, Pineda JA, Pasquau J, Masiá M, Crespo M, Blanco JR, Moreno S.

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

ANTIVIRAL RESEARCH 2015. 120: 79-84. Nº de citas: 11

[doi:10.1016/j.antiviral.2015.05.001]

Díaz L, Martínez-Bonet M, Sánchez J, Fernández-Pineda A, Jiménez JL, Muñoz E, Moreno S, Álvarez S, Muñoz-Fernández MÁ.

Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kappa B-dependent mechanism

SCIENTIFIC REPORTS 2015. 5: 12442-12442. Nº de citas: 44

[doi:10.1038/srep12442]

Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A, EuroSIDA in EuroCOORD.

HIV resistance testing and detected drug resistance in Europe

AIDS 2015. 29(11): 1379-1389. Nº de citas: 12

[doi:10.1097/QAD.0000000000000708]

Martínez-Bonet M, Clemente MI, Serramía MJ, Moreno S, Muñoz E, Muñoz-Fernández MA.

Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells::a possibility for HIV-1 paediatric patients?

Journal of virus eradication 2015. 1(3): 148-152. Nº de citas: 4

May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2015. 69(3): 348-354. Nº de citas: 34

[doi:10.1097/QAI.0000000000000603]

Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM, OLE/RIS-EST13 Study Group.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

LANCET INFECTIOUS DISEASES 2015. 15(7): 785-792. Nº de citas: 121

[doi:10.1016/S1473-3099(15)00096-1]

Aldámiz-Echevarría T, González-García J, Von Wichmann MA, Crespo M, López-Aldeguer J, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Bellón JM, Montes M, Berenguer J.

Association of baseline CD4+cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients

ANNALS OF HEPATOLOGY 2015. 14(4): 464-469. Nº de citas: 1

[doi:10.1016/S1665-2681(19)31167-6]